Six biotechnology stocks are moving up in their overall rating this week, according to the Portfolio Grader database. Every one of these is graded an “A” (“strong buy”) or “B” overall (“buy”).

This week, La Jolla Pharmaceutical Company (LJPC) is showing good progress as the company’s rating jumps from a B (“buy”) last week to an A (“strong buy”). In Portfolio Grader’s specific subcategories of Earnings Momentum and Earnings Revisions, LJPC also gets A’s. Shares of the stock have been changing hands at an unusually rapid pace, up 1045.7% from the week prior. For more information, get Portfolio Grader’s complete analysis of LJPC stock.

This week, Paratek Pharmaceuticals Inc (PRTK) pushes up from a B to an A rating. Shares of the stock have been trading at an exceptionally rapid pace, up 2518.4% from the week prior. For more information, get Portfolio Grader’s complete analysis of PRTK stock.

Incyte Corporation (INCY) ups its rating to a B (“buy”) this week after earning a C (“hold”) in the week before. Incyte is using its expertise in genomics and medicinal chemistry, as well as molecular, cellular, and in vivo biology to discover and develop novel therapeutics. Shares of the stock have been changing hands at an unusually rapid pace, up 484.7% from the week prior. For more information, get Portfolio Grader’s complete analysis of INCY stock.

Ambit Biosciences Corp. (AMBI) gets a higher grade this week, advancing from a C last week to a B. For more information, get Portfolio Grader’s complete analysis of AMBI stock.

This week, Progenics Pharmaceuticals, Inc.’s (PGNX) ratings are up from a C last week to a B. Progenics Pharmaceuticals develops and distributes therapeutic products to treat the unmet medical needs of patients with debilitating conditions and life-threatening diseases. Shares of the stock have been trading at an exceptionally rapid pace, up 459.9% from the week prior. For more information, get Portfolio Grader’s complete analysis of PGNX stock.

The rating of Celladon Corporation (CLDN) moves up this week, rising from a B to an A. Shares of the stock have been changing hands at an unusually rapid pace, four times the rate of the week prior. For more information, get Portfolio Grader’s complete analysis of CLDN stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.